Insider Buying: Actuate Therapeutics, Inc. (NASDAQ:ACTU) Director Purchases 71,428 Shares of Stock

Actuate Therapeutics, Inc. (NASDAQ:ACTU - Get Free Report) Director Aaron G.L. Fletcher acquired 71,428 shares of Actuate Therapeutics stock in a transaction dated Friday, June 27th. The shares were bought at an average cost of $7.00 per share, for a total transaction of $499,996.00. Following the completion of the purchase, the director directly owned 196,428 shares of the company's stock, valued at approximately $1,374,996. The trade was a 57.14% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Actuate Therapeutics Stock Performance

Shares of NASDAQ:ACTU traded down $0.22 during midday trading on Thursday, hitting $6.53. 53,986 shares of the stock traded hands, compared to its average volume of 58,310. The business's 50 day moving average is $8.95 and its two-hundred day moving average is $8.27. Actuate Therapeutics, Inc. has a one year low of $5.50 and a one year high of $11.99.

Actuate Therapeutics (NASDAQ:ACTU - Get Free Report) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.06).

Institutional Investors Weigh In On Actuate Therapeutics

Large investors have recently made changes to their positions in the business. BIOS Capital Management LP bought a new position in shares of Actuate Therapeutics during the fourth quarter valued at approximately $78,753,000. Voss Capital LP increased its position in Actuate Therapeutics by 157.7% during the 1st quarter. Voss Capital LP now owns 142,381 shares of the company's stock valued at $964,000 after purchasing an additional 87,135 shares during the period. Sigma Planning Corp raised its holdings in Actuate Therapeutics by 47.3% in the 1st quarter. Sigma Planning Corp now owns 23,675 shares of the company's stock worth $160,000 after purchasing an additional 7,600 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in Actuate Therapeutics by 98.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 22,358 shares of the company's stock worth $151,000 after purchasing an additional 11,105 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV purchased a new stake in shares of Actuate Therapeutics in the 4th quarter worth about $130,000.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Craig Hallum assumed coverage on Actuate Therapeutics in a research report on Tuesday, April 22nd. They issued a "buy" rating and a $21.00 price objective for the company. HC Wainwright lifted their target price on shares of Actuate Therapeutics to $20.00 and gave the stock a "buy" rating in a research note on Tuesday, June 3rd.

About Actuate Therapeutics

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.